Sphingosine 1-Phosphate Receptors and Metabolic Enzymes as Druggable Targets for Brain Diseases
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
The central nervous system is characterized by a high content of sphingolipids and by a high diversity in terms of different structures. Stage- and cell-specific sphingolipid metabolism and expression are crucial for brain development and maintenance toward adult age. On the other hand, deep dysregulation of sphingolipid metabolism, leading to altered sphingolipid pattern, is associated with the majority of neurological and neurodegenerative diseases, even those totally lacking a common etiological background. Thus, sphingolipid metabolism has always been regarded as a promising pharmacological target for the treatment of brain disorders. However, any therapeutic hypothesis applied to complex amphipathic sphingolipids, components of cellular membranes, has so far failed probably because of the high regional complexity and specificity of the different biological roles of these structures. Simpler sphingosine-based lipids, including ceramide and sphingosine 1-phosphate, are important regulators of brain homeostasis, and, thanks to the relative simplicity of their metabolic network, they seem a feasible druggable target for the treatment of brain diseases. The enzymes involved in the control of the levels of bioactive sphingoids, as well as the receptors engaged by these molecules, have increasingly allured pharmacologists and clinicians, and eventually fingolimod, a functional antagonist of sphingosine 1-phosphate receptors with immunomodulatory properties, was approved for the therapy of relapsing-remitting multiple sclerosis. Considering the importance of neuroinflammation in many other brain diseases, we would expect an extension of the use of such analogs for the treatment of other ailments in the future. Nevertheless, many aspects other than neuroinflammation are regulated by bioactive sphingoids in healthy brain and dysregulated in brain disease. In this review, we are addressing the multifaceted possibility to address the metabolism and biology of bioactive sphingosine 1-phosphate as novel targets for the development of therapeutic paradigms and the discovery of new drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome
Guy, J., Hendrich, B., Holmes, M., Martin, J. E., & Bird, A. (2001) · Nature Genetics · doi:10.1038/85899 · Cited by 1,558
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate
Hait, N. C., Allegood, J., Maceyka, M., Strub, G. M., Harikumar, K. B., Singh, S. K., Luo, C., Marmorstein, R., Kordula, T., Milstien, S., et al. (2009) · Science · doi:10.1126/science.1176709 · Cited by 997
The outs and the ins of sphingosine-1-phosphate in immunity
Spiegel, S., & Milstien, S. (2011) · Nature Reviews Immunology · doi:10.1038/nri2974 · Cited by 810
Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
Chun, J., & Hartung, H.-P. (2010) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3181cbf825 · Cited by 796
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
An update on the biology of sphingosine 1-phosphate receptors
Blaho, V. A., & Hla, T. (2014) · Journal of Lipid Research · doi:10.1194/jlr.r046300 · Cited by 516 · cited 7×
“Among them, S1P mediates crucial signaling pathways relevant to neurodegeneration (Hagen et al., 2011; Assi et al., 2013; Blaho and Hla, 2014; Proia and Hla, 2015; Pyne et al., 2018; Wang and Bieberich, 2018).”
BackgroundInfluentialDeregulation of sphingolipid metabolism in Alzheimer’s disease
He, X., Huang, Y., Li, B., Gong, C.-X., & Schuchman, E. H. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.05.010 · Cited by 516
Jazvinšćak Jembrek, M., Hof, P. R., & Šimić, G. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/346783 · Cited by 244 · cited 2×
“…PC12 cells is inhibited by the PI3K/Akt pathway (Safarian et al., 2015); 2) AP-1, regulated by the Jnk/p38/ERK pathway (Hsu et al., 2015; Jazvinscak Jembrek et al., 2015) and, in turn, controlling the mutual coregulation between sphingolipid-related genes (O’Neill et al., 2011; Huang et al., 2014;…”
BackgroundHait, N. C., Wise, L. E., Allegood, J. C., O'Brien, M., Avni, D., Reeves, T. M., Knapp, P. E., Lu, J., Luo, C., Miles, M. F., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3728 · Cited by 209
Kinase inhibitors modulate huntingtin cell localization and toxicity
Atwal, R. S., Desmond, C. R., Caron, N., Maiuri, T., Xia, J., Sipione, S., & Truant, R. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.582 · Cited by 204 · cited 1×
“This might contribute to the protective effect of fingolimod because this posttranslational modification was associated with reduced toxicity of mutated huntingtin (Atwal et al., 2011; Di Pardo et al., 2014).”
BackgroundGlucosylceramide synthase inhibition alleviates aberrations in synucleinopathy models
Sardi, S. P., Viel, C., Clarke, J., Treleaven, C. M., Richards, A. M., Park, H., Olszewski, M. A., Dodge, J. C., Marshall, J., Makino, E., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616152114 · Cited by 203
BACE1 activity is modulated by cell-associated sphingosine-1-phosphate
Takasugi, N., Sasaki, T., Suzuki, K., Osawa, S., Isshiki, H., Hori, Y., Shimada, N., Higo, T., Yokoshima, S., Fukuyama, T., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.6467-10.2011 · Cited by 181
Loss of the neuroprotective factor sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis
Couttas, T. A., Kain, N., Daniels, B., Lim, X. Y., Shepherd, C., Kril, J., Pickford, R., Li, H., Garner, B., & Don, A. S. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-9 · Cited by 161
Cross talk between PI3K-AKT-GSK-3β and PP2A pathways determines tau hyperphosphorylation
Wang, Y., Yang, R., Gu, J., Yin, X., Jin, N., Xie, S., Wang, Y., Chang, H., Qian, W., Shi, J., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.07.035 · Cited by 134 · cited 1×
“Finally, S1P, by acting on its receptors and affecting the downstream PI3K/Akt, can inhibit GSK-3β (the crucial tau kinase) (Wang et al., 2015) and the proapoptotic protein Bad (Czubowicz et al., 2019).”
BackgroundMiguez, A., García-Díaz Barriga, G., Brito, V., Straccia, M., Giralt, A., Ginés, S., Canals, J. M., & Alberch, J. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv218 · Cited by 126
Brito, V., Giralt, A., Enriquez-Barreto, L., Puigdellívol, M., Suelves, N., Zamora-Moratalla, A., Ballesteros, J. J., Martín, E. D., Dominguez-Iturza, N., Morales, M., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74809 · Cited by 114
Dusaban, S. S., Chun, J., Rosen, H., Purcell, N. H., & Brown, J. H. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-0882-x · Cited by 106
Gudi, V., Škuljec, J., Yildiz, Ö., Frichert, K., Skripuletz, T., Moharregh-Khiabani, D., Voß, E., Wissel, K., Wolter, S., & Stangel, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022623 · Cited by 103
Ghose, J., Sinha, M., Das, E., Jana, N. R., & Bhattacharyya, N. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023837 · Cited by 98 · cited 14×
“Moreover, evidence indicates that miRNA 125b expression, which is downregulated in R6/2 mice, negatively regulates gene expression of SGPL1 (Ghose et al., 2011; Yang et al., 2016).”
BackgroundInfluentialFTY720/fingolimod, a sphingosine analogue, reduces amyloid-β production in neurons
Takasugi, N., Sasaki, T., Ebinuma, I., Osawa, S., Isshiki, H., Takeo, K., Tomita, T., & Iwatsubo, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064050 · Cited by 85 · cited 1×
“Furthermore, both fingolimod and KRP203, another S1P analogue, decrease Aβ generation in neuronal cells (Takasugi et al., 2013).”
BackgroundMacrophages in CNS remyelination: friend or foe?
Diemel, L. T., Copelman, C. A., & Cuzner, M. L. (1998) · Neurochemical Research · doi:10.1023/a:1022405516630 · Cited by 78
Riganti, L., Antonucci, F., Gabrielli, M., Prada, I., Giussani, P., Viani, P., Valtorta, F., Menna, E., Matteoli, M., & Verderio, C. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3588-15.2016 · Cited by 78 · cited 1×
“…papers demonstrate that in hippocampal neurons, S1P is important for the stability of the presynaptic structure, for synaptic strength, and for the availability of synaptic vesicles (Brailoiu et al., 2002; Camoletto et al., 2009; Darios et al., 2009; Kanno et al., 2010; Riganti et al., 2016).”
BackgroundSelf-citationFingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis
Potenza, R. L., De Simone, R., Armida, M., Mazziotti, V., Pèzzola, A., Popoli, P., & Minghetti, L. (2016) · Neurotherapeutics · doi:10.1007/s13311-016-0462-2 · Cited by 69
Sphingolipids in Psychiatric Disorders and Pain Syndromes
Mühle, C., Reichel, M., Gulbins, E., & Kornhuber, J. (2013) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-7091-1511-4_22 · Cited by 58
Pyne, N. J., Adams, D. R., & Pyne, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.04.003 · Cited by 43
Neuronal sphingosine kinase 2 subcellular localization is altered in Alzheimer’s disease brain
Dominguez, G., Maddelein, M.-L., Pucelle, M., Nicaise, Y., Maurage, C.-A., Duyckaerts, C., Cuvillier, O., & Delisle, M.-B. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0527-z · Cited by 43
Sphingosine kinase 1-associated autophagy differs between neurons and astrocytes
Moruno-Manchon, J. F., Uzor, N.-E., Ambati, C. R., Shetty, V., Putluri, N., Jagannath, C., McCullough, L. D., & Tsvetkov, A. S. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0599-5 · Cited by 36
Cited by
Function and therapeutic value of astrocytes in neurological diseases
Lee, H.-G., Wheeler, M. A., & Quintana, F. J. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00390-x · Cited by 662
Quinville, B. M., Deschenes, N. M., Ryckman, A. E., & Walia, J. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115793 · Cited by 343
Giussani, P., Prinetti, A., & Tringali, C. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15133 · Cited by 91
Self-citationSphingolipids in neuroinflammation: a potential target for diagnosis and therapy
Lee, J. Y., Jin, H. K., & Bae, J.-S. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.278 · Cited by 80
“Unlike microglial SphK1 described in previous studies (12, 27-29), neuronal SphK1 levels are reduced in neuroinflam-”
BackgroundResultChung, H.-L., Ye, Q., Park, Y.-J., Zuo, Z., Mok, J.-W., Kanca, O., Tattikota, S. G., Lu, S., Perrimon, N., Lee, H. K., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.03.022 · Cited by 70
Metadata
- Authors
- Grassi, S., Mauri, L., Prioni, S., Cabitta, L., Sonnino, S., Prinetti, A., & Giussani, P.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2019-07-23
- Volume
- 10
- Pages
- 807-807
- ISSN
- 1663-9812 (ISSN-L)
- OpenAlex
- W2950329150
- Cited by
- 109
- References
- 28
- FWCI
- 3.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.